Professor of Medicine (Reg)
Center Director, Stem Cell Program and Gene Therapy Center, Institute for Regenerative Cures, UC Davis
UC Davis Institute for Regenerative Cures (IRC)
2921 Stockton Blvd.
Sacramento, CA 95817
Jan A. Nolta, Ph.D., is the director of the Stem Cell Program at UC Davis School of Medicine and directs the university’s Institute for Regenerative Cures. She also serves as scientific director of the large UC Davis Good Manufacturing Practice facility and the California Umbilical Cord Blood Collection Program. She was named one of the “Top 50 Global Stem Cell Influencers.”
The UC Davis Stem Cell Program has a large number of basic, translational and clinical members collaborating to work toward cell and gene therapies for a spectrum of diseases and injuries. The group she oversees at UC Davis’ Shared Translational Laboratory is helping university teams develop numerous clinical trials for gene and cell therapy. UC Davis currently has over 50 cell and/or gene therapies already in the clinic and more than 20 in the pipeline.
Malignant Hematology/Cellular Therapy and Transplantation
Hematology and Oncology
Institute for Regenerative Cures
Stem Cell Research Program
UC Davis Comprehensive Cancer Center
B.S., Biology, California State University, Sacramento, Sacramento CA 1984
M.S., Molecular Genetics, UC Davis, Davis CA 1987
Ph.D., Molecular Microbiology, University of Southern California, Los Angeles CA 1994
Stem Cell Therapy/Gene Therapy, Children's Hospital of Los Angeles, Los Angeles CA 1994-1997
Lifetime Leadership Award, Help 4 HD International, 2017
Honoree, Huntington's Disease Society of America, 2017
Biomedical Research Exemplar, The Research Exemplar Project, 2017
Honorable Recognition, UC Davis Women in Medicine in Health Sciences, 2016
Dean's Excellence in Mentoring Award, UC Davis Health System, 2013
For a list of Dr. Nolta's publications, please click here (opens new window).
Yang HY, Fierro F, Yoon DJ, Gallegos A, Osborn SL, Nguyen AV, Peavy TR, Ferrier W, Talken L, Ma BW, Galang KG, Medina Lopez A, Fregoso DR, Stewart H, Kurzrock EA, Soulika AM, Nolta JA, Isseroff RR. Combination product of dermal matrix, preconditioned human mesenchymal stem cells and timolol promotes wound healing in the porcine wound model. J Biomed Mater Res B Appl Biomater. 2022 Jul;110(7):1615-1623. doi:10.1002/jbm.b.35022. Epub 2022 Jan 31. PMID:35099112.
Nolta JA. Celebrating 40 Years as the Trusted Source for Stem Cell Manuscripts. Stem Cells. 2022 Mar 3;40(1):1. doi:10.1093/stmcls/sxab021. PMID:35511864.
Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products. Stem Cells Transl Med. 2022 Mar 3;11(1):2-13. doi:10.1093/stcltm/szab005. PMID:35641163.
Arzi B, Nolta JA, Vapniarsky N. The oromaxillofacial region as a model for a one-health approach in regenerative medicine. Am J Vet Res. 2022 Feb 16;83(4):291-297. doi:10.2460/ajvr.21.12.0208. PMID:35175935.
Deng P, Halmai JANM, Beitnere U, Cameron D, Martinez ML, Lee CC, Waldo JJ, Thongphanh K, Adhikari A, Copping N, Petkova SP, Lee RD, Lock S, Palomares M, O'Geen H, Carter J, Gonzalez CE, Buchanan FKB, Anderson JD, Fierro FA, Nolta JA, Tarantal AF, Silverman JL, Segal DJ, Fink KD. An in vivo Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models. Front Mol Neurosci. 2022 Jan 27;14:789913. doi:10.3389/fnmol.2021.789913. PMID:35153670.
Smithers RL, Kao HKJ, Zeigler S, Yechikov S, Nolta JA, Chan JW, Chiamvimonvat N, Lieu DK. Making Heads or Tails of the Large Mammalian Sinoatrial Node Micro-Organization. Circ Arrhythm Electrophysiol. 2021 Dec;14(12):e010465. doi:10.1161/CIRCEP.121.010465. Epub 2021 Nov 19. PMID:34794338.
Viswanathan S, Ciccocioppo R, Galipeau J, Krampera M, Le Blanc K, Martin I, Moniz K, Nolta J, Phinney DG, Shi Y, Szczepiorkowski ZM, Tarte K, Weiss DJ, Ashford P. Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy. 2021 Dec;23(12):1060-1063. doi:10.1016/j.jcyt.2021.04.009. Epub 2021 Jun 9. PMID:34116944.
Park UC, Park SS, Kim BH, Park SW, Kim YJ, Cary W, Anderson JD, Nolta JA, Yu HG. Subretinal versus intravitreal administration of human CD34+ bone marrow-derived stem cells in a rat model of inherited retinal degeneration. Ann Transl Med. 2021 Aug;9(15):1275. doi:10.21037/atm-20-4662. PMID:34532412.
Cheung KW, Yazdanyar A, Dolf C, Cary W, Marsh-Armstrong N, Nolta JA, Park SS. Analysis of the retinal capillary plexus layers in a murine model with diabetic retinopathy: effect of intravitreal injection of human CD34+ bone marrow stem cells. Ann Transl Med. 2021 Aug;9(15):1273. doi:10.21037/atm-20-3930. PMID:34532410.